Brain Natriuretic Peptide for Predicting Contrast-Induced Acute Kidney Injury in Patients with Acute Coronary Syndrome Undergoing Coronary Angiography: A Systematic Review and Meta-Analysis

Table 3

Results of sensitivity analysis and subgroup analysis.

Categories	Number of studies	Sensitivity (95% CI)/I^2	Specificity (95% CI)/I^2	AUC (95% CI)	DOR (95% CI)	PLR/NLR
All studies	9 [23–25, 35–40]	0.73 (0.65, 0.79)/58.95	0.79 (0.70, 0.85)/93.92	0.81 (0.77, 0.84)	10 (6, 17)	3.5/0.35
Biomarker
BNP	4 [35, 38–40]	0.69 (0.59, 0.78)/72.06	0.80 (0.67, 0.89)/97.22	0.78 (0.75, 0.82)	9 (4, 20)	3.4/0.39
NT-proBNP	5 [23–25, 36, 37]	0.77 (0.68, 0.83)/43.57	0.78 (0.66, 0.87)/84.33	0.82 (0.79, 0.85)	12 (7, 21)	3.5/0.30
Patient’s condition
STEMI	5 [24, 35, 37, 38, 40]	0.64 (0.57, 0.71)/9.1	0.83 (0.69, 0.92)/97.08	0.66 (0.62, 0.70)	9 (4, 21)	3.8/0.43
ACS	4 [23, 25, 36, 39]	0.81 (0.74, 0.86)/0	0.74 (0.69, 0.78)/69.06	0.85 (0.81, 0.88)	12 (7, 20)	3.1/0.26
Prospective study	7 [23–25, 36, 38–40]	0.76 (0.69, 0.82)/52.08	0.74 (0.67, 0.80)/90.41	0.82 (0.78, 0.85)	9 (5, 17)	2.9/0.32
Undergoing PCI	7 [23–25, 35, 38–40]	0.73 (0.65, 0.80)/65.65	0.78 (0.70, 0.84)/94.60	0.82 (0.78, 0.85)	10 (5, 17)	3.3/0.34

BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide; ACS, acute coronary syndrome; STEMI, ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; AUC, area under curve; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio and CI, credible interval.